Literature DB >> 26872106

Change in plasma a disintegrin and metalloprotease with thrombospondin type-1 repeats-13 and von Willebrand factor levels in venous thromboembolic patients.

Bulent Karakaya1, Anil Tombak2, Mehmet Sami Serin3, Naci Tiftik2.   

Abstract

OBJECTIVES: Venous thromboembolism (VTE) is an important cause of morbidity and mortality. A disintegrin and metalloprotease with thrombospondin type-1 repeats-13 (ADAMTS-13) is a metalloprotease that cleaves plasma von Willebrand factor (VWF) multimers. The presence of large VWF multimers in the plasma due to ADAMTS-13 deficiency is the main factor in the pathogenesis of thrombotic thrombocytopenic purpura. The present study aimed to investigate the relation of plasma levels of ADAMTS-13 and VWF antigen with VTE.
METHODS: The present study included 30 patients with VTE and age- and gender-matched 30 healthy subjects. Patients with any condition (diabetes, icterus, hyperlipidemia, physical, or surgical trauma, acute coronary syndrome, pregnancy, renal insufficiency, liver disease, malignancy, collagen tissue disease, chronic or acute inflammation, drug use affecting thrombocyte function) that could affect plasma VWF antigen or ADAMTS-13 levels were excluded. Plasma ADAMTS-13 and VWF antigen levels in the VTE and control groups were quantitatively determined by enzyme-linked immunosorbent assay method.
RESULTS: The median ADAMTS-13 level was 280 ng/ml (minimum-maximum, 70-1120 ng/ml) in the VTE group and 665 ng/ml (minimum-maximum, 350-2500 ng/ml) in the control group; the difference between the groups was significant (P < 0.0001). The mean VWF antigen level was 1750 ± 616 mU/ml in the patient group, which was significantly higher than that of the control group (950 ± 496 mU/ml) (P < 0.0001).
CONCLUSION: Significantly lower ADAMTS-13 levels and significantly higher VWF antigen levels were concluded to be the result of a pathological process rather than an etiological factor for VTE.

Entities:  

Keywords:  ADAMTS-13 protein; Blood coagulation; Thrombotic thrombocytopenic purpura; Venous thromboembolism; Von Willebrand factor

Mesh:

Substances:

Year:  2016        PMID: 26872106     DOI: 10.1080/10245332.2015.1125079

Source DB:  PubMed          Journal:  Hematology        ISSN: 1024-5332            Impact factor:   2.269


  4 in total

1.  Plasma levels of von Willebrand factor and future risk of incident venous thromboembolism.

Authors:  Magnus S Edvardsen; Kristian Hindberg; Ellen-Sofie Hansen; Vânia M Morelli; Thor Ueland; Pål Aukrust; Sigrid K Brækkan; Line H Evensen; John-Bjarne Hansen
Journal:  Blood Adv       Date:  2021-01-12

2.  ADAM and ADAMTS disintegrin and metalloproteinases as major factors and molecular targets in vascular malfunction and disease.

Authors:  HaiFeng Yang; Raouf A Khalil
Journal:  Adv Pharmacol       Date:  2022-01-24

3.  Elevated Von Willebrand Factor Antigen Levels are an Independent Risk Factor for Venous Thromboembolism: First Report from North India.

Authors:  Sweta Rajpal; Jasmina Ahluwalia; Narender Kumar; Pankaj Malhotra; Varun Uppal
Journal:  Indian J Hematol Blood Transfus       Date:  2019-02-15       Impact factor: 0.900

Review 4.  Pathogenesis of Two Faces of DVT: New Identity of Venous Thromboembolism as Combined Micro-Macrothrombosis via Unifying Mechanism Based on "Two-Path Unifying Theory" of Hemostasis and "Two-Activation Theory of the Endothelium".

Authors:  Jae C Chang
Journal:  Life (Basel)       Date:  2022-01-31
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.